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0167-8140/ 2020 Elsevier B.V. All rights reserved.To monitor and defeat further progression of the novel Coron-
avirus (COVID-19) infection, a strong public health vigilance has
been adopted in Italy [1]. By March 18, 31,772 cases were con-
firmed, with 2390 deaths [2]. The median age of patients who
are infected is 63 years and more than two-thirds of deaths have
occurred in elderly patients (aged 70 years) [2]. Hospitals’ work
regimes have been re-prioritized, but Coronavirus does not really
affect the cancer clinics. Although radiation oncologists are not
fighting on the front line, they have to guarantee treatment –
radiotherapy with or without concomitant chemotherapy ((C)RT)
– and, in the meantime, protect patients from the COVID-19
infection.
In this scenario, (C)RT has a crucial role in head and neck cancer
(HNC) management. It is the mainstay of treatment for most of the
HNC sites, because of its proven curative intent assuring an organ
preservation strategy [3–4]. HNC is a relatively rare cancer in Italy,
with 9300 new cases and 3216 deaths described per year [5]. Most
of the patients are diagnosed in a locally advanced stage disease
and should receive treatment as soon as possible. Therefore, during
this pandemic period, HNC patients represent a major clinical
problem with treatment decision-making process. Due to the com-
plexity in optimal strategy plan and patients’ support care through
treatment, the multidisciplinary team should weigh the risks and
the benefits to patients in deciding whether to modify patients’
work-up and treatment approach. We cannot provide specific
guidance on any other protocol of therapy – at this time, no clinical
HNC-specific data on COVID-19 are available – but we can state
that each decision requires an individualized risk/benefit assess-
ment. The aim should be to protect HNC patients without compro-
mising their oncologic outcome. It is paramount to stress open
channels of communication between administrators, clinicians,
patients and caregivers [6]. In order to assist shared decision-mak-
ing, multidisciplinary team meetings should be promoted using
web-platforms. A reasonable treatment strategy between anti-
cancer therapy and epidemic prevention should be selected. It
should be considered to: i) omit systemic therapy for patients
70 years or younger with co-morbidities, such as diabetes and
cardiovascular diseases. On the one hand, the updated meta-anal-
ysis of chemotherapy in head and neck cancer (MACH-NC) did not
show any survival benefit resulting from the addition of
chemotherapy for elderly patients [3]. On the other hand, these
relevant co-morbidities are linked to a higher risk of death in case
of COVID-19 infection [7]. ii) omit cisplatin-based induction
chemotherapy. A definitive benefit in overall survival with the
incorporation of induction chemotherapy compared to standard(C)RT has not been proven in randomized studies [8]. iii) short
overall treatment time. Definitive (C)RT should be limited to
simultaneous integrated boost (SIB) techniques in the standard
(5 fractions per week) or accelerated schedule (6 fractions per
week), in order to achieve a 1-week reduction compared to
sequential technique. SIB technique represents an optimum bal-
ance between tumor control and prevention of late toxicity excess
[9]. iv) delay post-operative RT in patients with salivary gland
tumors until 12 weeks after surgery. Time factor is not strictly
linked to adverse effect in these cases [10]. v) develop an online
surveillance plan. At present HNC patients deal with the double
ordeals of disease and pandemic situation. Patients should be edu-
cated to properly identify those symptoms and signs that poten-
tially signify a recurrence (increased local pain and difficulty in
swallowing, unexplained weight loss and development of new
lump in the head and neck region). For sure, patients should be
informed regarding the Coronavirus symptoms (mainly fever, dys-
pnea and cough) and educated in proper hand washing and all
other measures to limit viral transmission (avoid touching your
eyes, nose and mouth; cover your nose and mouth with a tissue
when you cough or sneeze; clean and disinfect high touch surfaces
regularly; stop shaking hands or kissing as a greeting; reduce
exposure to sick contacts and large crowds). Psychological coun-
seling should be paid attention to through seeking alternative
schemes.
It must be appreciated that this document is an attempt to pro-
vide practical suggestions on how to define a reasonable treatment
strategy and mitigate the COVID-19 impact on HNC patients under
the current pandemic conditions. It is necessary to offer adequate
individualized treatment recommendations based on both the epi-
demic situation and the patient’s own condition. We significantly
hope to help HNC patients to survive this difficult period.
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